Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H6ClN3O4S2.ClH |
Molecular Weight | 332.184 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NS(=O)(=O)C1=C(Cl)C=C2N=CNS(=O)(=O)C2=C1
InChI
InChIKey=GQWPZOKTQKQAPN-UHFFFAOYSA-N
InChI=1S/C7H6ClN3O4S2.ClH/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5;/h1-3H,(H,10,11)(H2,9,12,13);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C7H6ClN3O4S2 |
Molecular Weight | 295.723 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00880Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/diuril-injection.html
Sources: http://www.drugbank.ca/drugs/DB00880
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/diuril-injection.html
Like other thiazides, chlorothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk. As a diuretic, chlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like chlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of chlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. It is marketed under the brand name Diuril.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13802826
Curator's Comment: Chlorothiazide was synthesized by Novello and Sprague in 1957
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL261 Sources: http://www.drugbank.ca/drugs/DB00880 |
|||
Target ID: CHEMBL205 Sources: http://www.drugbank.ca/drugs/DB00880 |
|||
Target ID: CHEMBL3729 Sources: http://www.drugbank.ca/drugs/DB00880 |
|||
Target ID: CHEMBL1876 Sources: http://www.drugbank.ca/drugs/DB00880 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Diuril Approved UseIntravenous Sodium DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Intravenous Sodium DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Launch Date1958 |
|||
Primary | Diuril Approved UseIntravenous Sodium DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Intravenous Sodium DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Launch Date1958 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
682.97 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19902362 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLOROTHIAZIDE plasma | Sus scrofa population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
806.27 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19902362 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLOROTHIAZIDE plasma | Sus scrofa population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19902362 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLOROTHIAZIDE plasma | Sus scrofa population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1000 mg 2 times / day multiple, oral Recommended Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Edema|Hypertension Sources: Page: p.4 |
Disc. AE: Hypersensitivity, Azotemia... AEs leading to discontinuation/dose reduction: Hypersensitivity Sources: Page: p.4Azotemia Systemic lupus erythematosus reactivation |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Azotemia | Disc. AE | 1000 mg 2 times / day multiple, oral Recommended Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Edema|Hypertension Sources: Page: p.4 |
Hypersensitivity | Disc. AE | 1000 mg 2 times / day multiple, oral Recommended Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Edema|Hypertension Sources: Page: p.4 |
Systemic lupus erythematosus reactivation | Disc. AE | 1000 mg 2 times / day multiple, oral Recommended Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Edema|Hypertension Sources: Page: p.4 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: abstract |
no | |||
Page: abstract |
no | |||
Page: abstract |
weak [IC50 2205 uM] | |||
Page: abstract |
weak [IC50 2632 uM] | |||
Page: 9.0 |
yes [IC50 212 uM] | |||
Page: abstract |
yes [IC50 3.78 uM] | |||
Page: abstract |
yes [IC50 65.3 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
Page: 3.0 |
yes | |||
Page: S34 |
yes | |||
Page: S34 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Lithium-induced diabetes insipidus: manic symptoms, brain and electrolyte correlates, and chlorothiazide treatment. | 1973 Sep |
|
Hyperosmolality complicating recovery from lithium toxicity. | 1978 Jun 10 |
|
Thiazide-induced hyponatremia. | 1983 Nov |
|
Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate. | 1989 Mar |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Healing virtue: Saludadores versus witches in early modern Spain. | 2009 |
|
Impacts of intensive agricultural irrigation and livestock farming on a semi-arid Mediterranean catchment. | 2010 Aug |
|
Running away experience and psychoactive substance use among adolescents in Taiwan: multi-city street outreach survey. | 2010 Jan 20 |
|
Speeding up the process urine sample pre-treatment: some perspectives on the use of microwave assisted extraction in the anti-doping field. | 2010 Jun 15 |
|
Surgical anatomy of the lower eyelid relating to lower blepharoplasty. | 2010 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/diuril-injection.html
The usual adult dosage is 0.5 to 1 g once or twice a day.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8914012
Chlorothiazide (1000 uM) inhibited osteocalcin secretion (-42 +/- 12.7%) in human model cell line MG-63
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:25:28 GMT 2023
by
admin
on
Sat Dec 16 18:25:28 GMT 2023
|
Record UNII |
JCS5G4J7AC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
17278-61-4
Created by
admin on Sat Dec 16 18:25:29 GMT 2023 , Edited by admin on Sat Dec 16 18:25:29 GMT 2023
|
PRIMARY | |||
|
129846846
Created by
admin on Sat Dec 16 18:25:29 GMT 2023 , Edited by admin on Sat Dec 16 18:25:29 GMT 2023
|
PRIMARY | |||
|
JCS5G4J7AC
Created by
admin on Sat Dec 16 18:25:29 GMT 2023 , Edited by admin on Sat Dec 16 18:25:29 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|